KROS
Keros Therapeutics, Inc. Common StockData: 2026-10-22
Quick Stats
Oct 22, 202658.3
AI Score
BUY0.6
Volume Ratio
Nov 04, 2026
Next Earnings
15
+ve Days (30d)
15
-ve Days (30d)
KROS Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
KROS Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
KROS Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KROS Daily Out of Money Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KROS Daily In the Money Options - Sort by Max open Interest (near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KROS Most Active Options by Volume(near term)
23rd October 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
KROS Technical Chart Pro Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Volume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
KROS Stock Summary
Last updated Oct 22, 2026
KROS is currently trading at $11.35, positioned below its 200-day moving average of $12.29, suggesting bearish momentum. The stock has a 52-week range of $9.69 to $22.55.
Technical Analysis: The 50-day moving average stands at $11.19, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 51.385, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.022, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates KROS at 58.3/100 with a BUY recommendation.
KROS (Keros Therapeutics, Inc. Common Stock) Indicators
Last updated Oct 22, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 51.385 |
| CMF (20) | 0.022 |
| ROC (10) | -2.491 |
| ADX (14) | 14.12 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | -0.004 |
| AROONOSC (14) | -35.714 |
| WILLAMS %R (14) | -55.828 |
| MFI (14) | 43.25 |
KROS Candlestick Patterns
Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.
| Date | Pattern | Signal | 5-Day Hit Rate | Edge vs Baseline | Sample |
|---|---|---|---|---|---|
| Oct 16 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
| Oct 13 | Three Inside Down (contrarian — textbook says the opposite) | Bullish | 56.9% | +3.9 pts | 8868 |
| Oct 13 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.
Keros Therapeutics, Inc. Common Stock is above the 50 Day SMA but below the 200 Day SMA — short-term strength within a longer-term downtrend (Mixed).
KROS Moving Averages Analysis
Keros Therapeutics, Inc. Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Oct 22, 2026
KROS (Keros Therapeutics, Inc. Common Stock) Simple Moving Averages
Moving Averages are last updated Oct 22, 2026
| Days | MA |
|---|---|
| 10 | 11.26 |
| 20 | 11.3 |
| 30 | 11.31 |
| 50 | 11.19 |
| 100 | 10.9 |
| 200 | 12.29 |
KROS Fundamental Analysis
| P/E (Forward) | 48.7805 |
| P/E (Trailing) | -- |
| Market Cap ($) | 221.7 million |
| Earnings/Share ($) | -3.22 |
| Net Profit Margin (%) | -- |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -5.22 |
| EPS Estimate Next Year ($) | -6.616 |
| WallStreet Target Price ($) | 19.83 |
| Most Recent Quarter |
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.